Biological evaluation of new vitamin D2 analogues

Research output: Contribution to journalArticle

Standard

Biological evaluation of new vitamin D2 analogues. / Corcoran, Aoife; Bermudez, Maria A.; Seoane, Samuel; Perez-fernandez, Roman; Krupa, Małgorzata; Pietraszek, Anita; Chodyński, Michał; Kutner, Andrzej; Brown, Geoffrey.; Marcinkowska, Ewa.

In: The Journal of Steroid Biochemistry and Molecular Biology, 30.09.2015.

Research output: Contribution to journalArticle

Harvard

Corcoran, A, Bermudez, MA, Seoane, S, Perez-fernandez, R, Krupa, M, Pietraszek, A, Chodyński, M, Kutner, A, Brown, G & Marcinkowska, E 2015, 'Biological evaluation of new vitamin D2 analogues', The Journal of Steroid Biochemistry and Molecular Biology. https://doi.org/10.1016/j.jsbmb.2015.09.033

APA

Corcoran, A., Bermudez, M. A., Seoane, S., Perez-fernandez, R., Krupa, M., Pietraszek, A., Chodyński, M., Kutner, A., Brown, G., & Marcinkowska, E. (2015). Biological evaluation of new vitamin D2 analogues. The Journal of Steroid Biochemistry and Molecular Biology. https://doi.org/10.1016/j.jsbmb.2015.09.033

Vancouver

Corcoran A, Bermudez MA, Seoane S, Perez-fernandez R, Krupa M, Pietraszek A et al. Biological evaluation of new vitamin D2 analogues. The Journal of Steroid Biochemistry and Molecular Biology. 2015 Sep 30. https://doi.org/10.1016/j.jsbmb.2015.09.033

Author

Corcoran, Aoife ; Bermudez, Maria A. ; Seoane, Samuel ; Perez-fernandez, Roman ; Krupa, Małgorzata ; Pietraszek, Anita ; Chodyński, Michał ; Kutner, Andrzej ; Brown, Geoffrey. ; Marcinkowska, Ewa. / Biological evaluation of new vitamin D2 analogues. In: The Journal of Steroid Biochemistry and Molecular Biology. 2015.

Bibtex

@article{0c1270cf2e6c45efa35b5f354dce3a1b,
title = "Biological evaluation of new vitamin D2 analogues",
abstract = "1,25-dihydroxyvitamin D3 (1,25D), a steroid hormone which regulates calcium/phosphate homeostasis, has a broad spectrum of anti-cancer activities, including differentiation of acute myeloid leukemia (AML) cells. In order to avoid undesirable side effects such as hypercalcemia, low-calcemic analogues should be produced for therapeutic purposes. In this paper, we describe biological activities of double-point modified analogues of vitamin D2 and we compare them to 1,25D and to paricalcitol, the drug used to treat secondary hyperparathyroidism. In vivo, our new analogues have lower calcemic effects, and lower toxicity in comparison to 1,25D. They have enhanced pro-differentiating and transcription-inducing activities in AML cells. Interestingly, differentiation effects do not correlate with the affinities of the analogues to the vitamin D receptor (VDR).",
keywords = "vitamin D analogues, vitamin D receptor, leukemia, differentiation, calcemic effects, keratinocytes",
author = "Aoife Corcoran and Bermudez, {Maria A.} and Samuel Seoane and Roman Perez-fernandez and Ma{\l}gorzata Krupa and Anita Pietraszek and Micha{\l} Chody{\'n}ski and Andrzej Kutner and Geoffrey. Brown and Ewa Marcinkowska",
year = "2015",
month = sep
day = "30",
doi = "10.1016/j.jsbmb.2015.09.033",
language = "English",
journal = "The Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Biological evaluation of new vitamin D2 analogues

AU - Corcoran, Aoife

AU - Bermudez, Maria A.

AU - Seoane, Samuel

AU - Perez-fernandez, Roman

AU - Krupa, Małgorzata

AU - Pietraszek, Anita

AU - Chodyński, Michał

AU - Kutner, Andrzej

AU - Brown, Geoffrey.

AU - Marcinkowska, Ewa

PY - 2015/9/30

Y1 - 2015/9/30

N2 - 1,25-dihydroxyvitamin D3 (1,25D), a steroid hormone which regulates calcium/phosphate homeostasis, has a broad spectrum of anti-cancer activities, including differentiation of acute myeloid leukemia (AML) cells. In order to avoid undesirable side effects such as hypercalcemia, low-calcemic analogues should be produced for therapeutic purposes. In this paper, we describe biological activities of double-point modified analogues of vitamin D2 and we compare them to 1,25D and to paricalcitol, the drug used to treat secondary hyperparathyroidism. In vivo, our new analogues have lower calcemic effects, and lower toxicity in comparison to 1,25D. They have enhanced pro-differentiating and transcription-inducing activities in AML cells. Interestingly, differentiation effects do not correlate with the affinities of the analogues to the vitamin D receptor (VDR).

AB - 1,25-dihydroxyvitamin D3 (1,25D), a steroid hormone which regulates calcium/phosphate homeostasis, has a broad spectrum of anti-cancer activities, including differentiation of acute myeloid leukemia (AML) cells. In order to avoid undesirable side effects such as hypercalcemia, low-calcemic analogues should be produced for therapeutic purposes. In this paper, we describe biological activities of double-point modified analogues of vitamin D2 and we compare them to 1,25D and to paricalcitol, the drug used to treat secondary hyperparathyroidism. In vivo, our new analogues have lower calcemic effects, and lower toxicity in comparison to 1,25D. They have enhanced pro-differentiating and transcription-inducing activities in AML cells. Interestingly, differentiation effects do not correlate with the affinities of the analogues to the vitamin D receptor (VDR).

KW - vitamin D analogues

KW - vitamin D receptor

KW - leukemia

KW - differentiation

KW - calcemic effects

KW - keratinocytes

U2 - 10.1016/j.jsbmb.2015.09.033

DO - 10.1016/j.jsbmb.2015.09.033

M3 - Article

JO - The Journal of Steroid Biochemistry and Molecular Biology

JF - The Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

ER -